StaphVAX vaccine data

UNVX (Rockville, Md.) announced that an analysis of a quarter of the data from a Phase II trial is showing that the formulation is unable to induce sufficient immunogenicity.

The first six months of data from 100 of the 239 dialysis patients was reviewed, and while many had a good response, the percentage of responders was not high enough to warrant proceeding with the product into a Phase III trial this year as planned, the company told BioCentury. A complete analysis of the data will be available in the third quarter. ...